Claims
- 1) A method for reducing or eliminating a decrease in neurosensory retinal function following laser treatment of chorodial neovascularization (CNV) while maintaining the vascular occlusion therapeutic effect of such therapy, the method comprising the steps: a) administering to a mammal having a CNV a therapeutically effective amount of an alpha receptor agonist, b) subjecting said mammal to laser irradiation of the retinal locus of the CNV; wherein the amount of neurosensory retinal function following steps a) and b) is greater than when said mammal is subjected to step b) without step a).
- 2) The method of claim 1 wherein the alpha adrenergic receptor agonist is an alpha 2 selective agonist.
- 3) The method of claim 2 wherein the alpha adrenergic receptor agonist is selected from the group consisting of brinoinidine, clonidine, and para-aminoclonidine.
- 4) The method of claim 3 in which the alpha adrenergic receptor agonist is brimonidine.
- 5) The method of claim 2 wherein the alpha 2 selective agonist is an alpha 2B and/or 2C selective agonist.
- 6) The method of claim 3 wherein the alpha 2 selective agonist is an alpha 2B selective agonist.
- 7) The method of claim 6 in which the alpha 2B selective agonist is selected from the group consisting of AGN 960, AGN 795 and AGN 923.
- 8) The method of claim 7 in which the alpha 2B selective agonist is AGN 960.
- 9) The method of claim 7 in which the alpha 2B selective agonist is AGN 795.
- 10) The method of claim 7 in which the alpha 2B selective agonist is AGN 923.
- 11) The method of claim 4 wherein the alpha 2 selective agonist is an alpha 2B specific agonist.
- 12) The method of claim 1 wherein prior to step b) said method comprises: administering to said patient a therapeutically effective amount of a photoactive agent in a manner such that said photoactive agent is present in the CNV during step b).
- 13) A method of protecting ocular neural tissue from damage caused by electromagnetic irradiation of the retina comprising delivering to a patient's ocular neural tissue an amount of a neuroprotectant compound effective to protect a plurality of ocular neurons from cell death as compared to ocular neuron cell death following such irradiation observed in the absence of the administration of said neuroprotectant.
- 14) The method of claim 13 wherein said electromagnetic irradiation is laser irradiation.
- 15) The method of claim 13 wherein said neuroprotectant compound is an alpha adrenergic agonist.
- 16) The method of claim 13 wherein said alpha adrenergic agonist is an alpha 2 selective agonist.
- 17) The method of claim 16 wherein said alpha 2 selective agonist is selected from the group consisting of brimonidine, clonidine and para-aminoclonidine.
- 18) The method of claim 17 wherein said compound is brimonidine.
- 19) The method of claim 13 wherein said alpha adrenergic receptor agonist is an alpha 2B and/or alpha 2C selective agonist.
- 20) The method of claim 19 wherein said alpha 2B and/or alpha 2C selective agonist is selected from the group consisting of AGN 960, AGN 795 and AGN 923.
- 21) The method of claim 20 in which the alpha 2B selective agonist is AGN 960.
- 22) The method of claim 20 in which the alpha 2B selective agonist is AGN 795.
- 23) The method of claim 20 in which the alpha 2B selective agonist is AGN 923.
- 24) The method of claim 13 wherein said neuroprotectant compound is administered at a time sufficiently before said electromagnetic irradiation to permit localization within ocular tissue prior to said treatment.
- 25) The method of claim 13 wherein said neuroprotectant compound is administered following said electromagnetic irradiation.
Parent Case Info
[0001] This application claims priority pursuant to 35 USC 119 to provisional application Serial No. 60/244,850, filed Nov. 1, 2000.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60244850 |
Nov 2000 |
US |